Immunoprecise Antibodies Liabilities 2024

Immunoprecise Antibodies Aktienanalyse

What does Immunoprecise Antibodies do?

Immunoprecise Antibodies Ltd is a leading company in the development of antibodies and antibody-based solutions for the pharmaceutical and biotech industry. The company was founded in 2015 as a spin-off from the University of Victoria in Canada and has since experienced rapid growth, expanding into other countries such as the USA, Europe, and Asia. The company's unique business model is based on three pillars: providing innovative research services tailored to the needs of the pharmaceutical and biotech industry, offering a broad portfolio of antibody products for research and diagnostics, and developing a pipeline of new therapeutics currently undergoing clinical trials. The core business of Immunoprecise Antibodies Ltd is the manufacturing of antibodies and antibody-based solutions for research and diagnostics. The company offers a range of innovative services, including antibody engineering, production and purification, and characterization. The research services are provided by an experienced team of scientists and experts in the field of antibody research who work closely with customers to meet their specific needs. In addition, the company has a wide range of antibody products available for various applications in research and diagnostics, including protein quantification, immunohistochemistry, cancer antigen detection, influenza diagnostics, and many others. Immunoprecise Antibodies Ltd has also developed a pipeline of new therapeutics, including antibodies against cancer, inflammation, and infectious diseases, which are currently undergoing clinical trials. The company collaborates closely with leading pharmaceutical and biotech companies to advance the latest developments in this field. To enable better focus and specialization, Immunoprecise Antibodies Ltd is divided into six divisions: humanization/antibody engineering, antibody production, antibody characterization, immunohistochemistry, therapeutics development, and process development. These divisions are strategically designed to cover the needs of customers and facilitate an effective supply chain for antibody production and development. Immunoprecise Antibodies Ltd is a young and dynamic company with a strong focus on innovation and customer satisfaction. It has earned an excellent reputation in the industry and is regarded as a valuable partner for antibody research and development by leading pharmaceutical and biotech companies. The company's goal is to remain a key player in the field of antibody research and continue developing innovative solutions for the pharmaceutical and biotech industry. Immunoprecise Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Immunoprecise Antibodies's Liabilities

Immunoprecise Antibodies's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Immunoprecise Antibodies's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Immunoprecise Antibodies's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Immunoprecise Antibodies's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Immunoprecise Antibodies’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Immunoprecise Antibodies stock

What is the level of liabilities of Immunoprecise Antibodies this year?

Immunoprecise Antibodies has a debt balance of 20.01 M CAD this year.

What were the liabilities of Immunoprecise Antibodies compared to the previous year?

The liabilities of Immunoprecise Antibodies have increased by 8.98% increased compared to the previous year.

What are the consequences of high debt for investors of Immunoprecise Antibodies?

High liabilities can pose a risk for investors of Immunoprecise Antibodies, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Immunoprecise Antibodies?

Low liabilities mean that Immunoprecise Antibodies has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Immunoprecise Antibodies affect the company?

An increase in liabilities of Immunoprecise Antibodies can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Immunoprecise Antibodies affect the company?

A decrease in the liabilities of Immunoprecise Antibodies can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Immunoprecise Antibodies?

Some factors that can influence the liabilities of Immunoprecise Antibodies include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Immunoprecise Antibodies so important for investors?

The liabilities of Immunoprecise Antibodies are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Immunoprecise Antibodies take to modify the liabilities?

To change its liabilities, Immunoprecise Antibodies can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Immunoprecise Antibodies pay?

Over the past 12 months, Immunoprecise Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Immunoprecise Antibodies is expected to pay a dividend of 0 CAD.

What is the dividend yield of Immunoprecise Antibodies?

The current dividend yield of Immunoprecise Antibodies is .

When does Immunoprecise Antibodies pay dividends?

Immunoprecise Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Immunoprecise Antibodies?

Immunoprecise Antibodies paid dividends every year for the past 0 years.

What is the dividend of Immunoprecise Antibodies?

For the upcoming 12 months, dividends amounting to 0 CAD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Immunoprecise Antibodies located?

Immunoprecise Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Immunoprecise Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Immunoprecise Antibodies from 9/27/2024 amounting to 0 CAD, you needed to have the stock in your portfolio before the ex-date on 9/27/2024.

When did Immunoprecise Antibodies pay the last dividend?

The last dividend was paid out on 9/27/2024.

What was the dividend of Immunoprecise Antibodies in the year 2023?

In the year 2023, Immunoprecise Antibodies distributed 0 CAD as dividends.

In which currency does Immunoprecise Antibodies pay out the dividend?

The dividends of Immunoprecise Antibodies are distributed in CAD.